Navigation Links
Researchers find drug-eluting stents safe, effective for PCI in diabetics

SAN FRANCISCO, CA ─ SEPTEMBER 21, 2009 Results of a multicenter study in Asia, demonstrating that drug-eluting stents are effective with a low rate of complications in diabetic patients, will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

The study, "The Effect of Drug-Eluting Stents on Clinical and Angiographic Outcomes in Diabetic Patients: Multicenter Registry in Asia," compared the safety and efficacy of sirolimus (SES), paclitaxel (PES), zotarolimus ( ZES), biolimus A9 (BES) and everolimus-eluting (EES) stents on the outcome of percutaneous coronary intervention (PCI) in patients with diabetes mellitus (DM).

The study will be presented as a poster abstract (TCT-363) on Tuesday, September 22 between 8:00 a.m. and 10:00 a.m. in Hall D of The Moscone Center. Sunao Nakamura, MD, lead investigator for the study, will report on the results of the investigations. Dr. Nakamura is Vice President and Director of the Cardiovascular Center at New Tokyo Hospital as well as Clinical and Visiting Professor of Kumamoto University in Matsudo, Japan.

The investigation consisted of a prospective analysis of 1,373 patients with DM treated with different drug-eluting stents (508 SES, 420 PES, 204 ZES, 120 BES and 121 EES) in six high-volume Asian centers. The study endpoints were the incidence of MACE at 30 days, the restenosis rate at 9 months and target lesion revascularization (TLR) at 9 months.

The incidence of MACE with this study cohort was 0.8% in patients receiving SES, 1.2% in PES, 1.0% in ZES, 0.8% in BES and 0.0% in EES. The restenosis rate at 9 months was 7.9% for those receiving SES, 12.6% for PES, 16.2% for ZES, 5.0% for BES and 6.7% for EES. TLR at 9 months was 6.5% in patients receiving SES, 10.7% with PES, 13.7% with ZES, 5.0% with BES and 4.1% with EES.

The researchers concluded that the use of drug-eluting stents in patients with DM was safe with low acute complications. Further, patients treated with SES, BES and EES showed a lesser rate of restenosis when compared with other drug-eluting stents.


Contact: Judy Romero
Cardiovascular Research Foundation

Related medicine news :

1. Researchers Propose Improved Cervical Cancer Screening
2. Researchers Perfect the View of Heart Disease
3. Mayo Clinic researchers lead national trial testing new treatment for chronic, severe indigestion
4. Indiana U medical researchers boost research and jobs with stimulus legislation grants
5. Canadian researchers discover the first-ever link between intelligence and curiosity
6. MUSC Researchers Concerned About Online Drug Availability
7. UCLA researchers develop biomarker for rapid relief of major depression
8. UCSB researchers develop drug delivery system using nanoparticles and lasers
9. University of Arizona researchers seek safer cystic fibrosis test
10. UAB researchers find TB-prevention therapy is cost-effective option
11. U of T researchers identify protein
Post Your Comments:
(Date:11/27/2015)... ... 2015 , ... Consistent with the Radiology Business Management ... Radiology Marketing Programs meeting will showcase some of the best 2015 radiology ... Palace in Las Vegas with a pre-conference session on a collaborative approach for ...
(Date:11/27/2015)... Minn. (PRWEB) , ... November 27, 2015 , ... ... start failing. Secura Consultants has prided itself for not only fulfilling the needs ... income protection solutions at an affordable price and providing top-tier customer service. However, ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... largest, most successful and prominent nonprofit healthcare organizations in the country. They have ... with various organizations, and helped advance the healthcare industry as a whole through ...
(Date:11/27/2015)... ... , ... Indosoft Inc., developer and distributor of the world-class ... (Long Term Support) into its Q-Suite 5.10 product line. , Making the change ... version of Asterisk that will receive not only security fixes, but feature and ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD ... for diagnostic imaging in the Waterloo region. Using the Ocean Platform, family physicians ... directly from their electronic medical record (EMR) without the need for redundant patient ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015 On Tuesday, ... federal bellwether trial against Wright Medical Technology, Inc. ... their Conserve metal-on-metal hip implant device, awarded $11 ... a two week trial and three days of ... hip device was defectively designed and unreasonably dangerous, ...
(Date:11/25/2015)... Nov. 25, 2015  Henry Schein, Inc., the world,s ... office-based dental, medical and animal health practitioners, will unveil ... Henry Schein ConnectDental® Pavilion , which brings together ... open solutions designed to help any practice or laboratory ... for a schedule of experts appearing at the ...
(Date:11/25/2015)... 2015 Allergan plc (NYSE: AGN ) today ... New York State Attorney General,s Office to ... and other statutes with the Attorney General over the decision ... marketing and selling the now generic version of memantine immediate ... liability, has released its counterclaims against New York ...
Breaking Medicine Technology: